QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-leap-therapeutics-down-9-in-pre-market-trading

Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.

 leap-therapeutics-secures-589m-pipe-led-by-winklevoss-capital-for-9585m-shares-and-warrants-to-buy-719m-shares

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

 leap-therapeutics-reports-updated-results-from-part-b-of-defiance-phase-2-study-of-sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-vs-bevacizumab-and-chemotherapy-for-advanced-microsatellite-stable-colorectal-cancer

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEG...

 leap-therapeutics-q1-eps-037-beats-038-estimate

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-neutral-on-leap-therapeuticsto-neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) from Neutral to Neutral.

 penny-stock-leap-therapeutics-unveils-positive-data-from-experimental-combo-therapy-for-colorectal-cancer

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with on...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION